| Biomarker ID | 803 |
| PMID | 22071976 |
| Year | 2011 |
| Biomarker | LRRN3+PCDH17+HIST1H4C+PGLYRP1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(LRRN3):-TSH regulation of gene expression,Interleukin-4 regulation of apoptosis |
| Experiment | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination |
| Type of Biomarker | Prognostic |
| Cohort | 164 patients with metastatic castration-resistant prostate cancer were chosen. Out of which 40 were chosen as control set: (survived for >900 days (long-term survivors n =20) or died within 300 days (short-term survivors n=20). The rest are chosen as validation set. |
| Senstivity | Train: 85%; Test: 100% |
| Specificity | Train: 75%; Test: 83% |
| AUC | NA |
| Accuracy | Train; 80%; Test: 92% |
| Level Of Significance | p< 0.008 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Personalised Peptide vaccines were given to patients |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | LRRN3, PCDH17, H4-16, PGLYRP1 |